Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC By Ogkologos - May 19, 2026 244 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PLANeT study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR FDA Amends Indication for Pembrolizumab in the First-Line Treatment for Patients... November 30, 2023 Three cancer drugs approved for NHS use in Scotland November 11, 2021 Binimetinib Contributes to the Efficacy and Safety Outcomes Observed with Encorafenib... September 4, 2023 Data from a Large Cohort of Patients with mRCC Demonstrate the... September 21, 2020 Load more HOT NEWS Copanlisib Could Be a Viable Therapeutic Option for Select PIK3CA-Mutated Cancers FDA Approves Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer Foodie Fridays-Gazpacho: A Favorite Summer Soup Severe mental illness linked to low attendance at cancer screening
